AHCL vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. ANLON HEALTHCARE shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AHCL leads 4; SYMBIOTEC leads 2 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| Live Price | ₹27 | ₹1,513.6 |
| Day Change | -3.54% | 19.04% |
| Volume | 44.68 L | 75.4 L |
| 52-Week High | ₹161 | ₹1,309.9 |
| 52-Week Low | ₹12.91 | ₹934.2 |
| Distance from 52W High | -83.23% | 15.55% |
Valuation
| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹1,435 Cr | ₹9,799 Cr |
| P/E Ratio | 45x | — |
| P/B Ratio | 5.58x | — |
| EPS | ₹0.25 | ₹2.24 |
| Book Value | ₹4.79 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 4% | 0% |
| EPS Growth (TTM YoY) | -54.8% | 0% |
| Qtr Sales Growth | 20.61% | 0% |
| Qtr Profit Growth | 107.43% | 0% |
Profitability & Leverage
| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| ROE | 11.42% | — |
| ROCE | 10.76% | — |
| Net Margin | 22.18% | 0% |
| Operating Margin | 26.89% | — |
| Debt to Equity | 0.17x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AHCL | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 52.68% | 33.28% |
| FII Holding | 1%▼ 0.67 pp | 3.79%▼ 17.29 pp |
| DII Holding | 0.3%▼ 0.92 pp | 33.17%▲ 5.65 pp |
| Public Holding | 46.02%▲ 1.59 pp | 29.76%▲ 11.64 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANLON HEALTHCARE and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.